Genscript (1548.HK): 1H26 Results Driven by AI Orders; Guidance Upgrades on Life-Science and Probio
1H26 results driven by AI orders; 2026 guidance upgrade on Life science and Probio; at US$7.2bn mkt cap (vs TWST: US$7.4bn), our quick back-of...
110 Views
Technically Speaking Breakouts & Breakdowns - HONG KONG (August 2026)
Genscript shares gain after the company announced it will provide wet-lab services to companies participating in Eli Lilly's TundeLab, helping them...
118 Views
China Healthcare Weekly Wrap (14-18 Sep)
Key news over the week: 1) WCLC cancer conference updates, 2) AI news flows (TuneLab/Genscript, Harbour Bio, ByteDance's Anew Labs), 3)others:...
100 Views
China Healthcare Weekly Wrap (7-11 Sep)
1) Insilico AI drug could slow aging indicated by early data; 2) Genscript US$300m placing for AIDD capex; 3) two long-acting TSLP-targeting drugs...
88 Views
Primer: Genscript Biotech (1548 HK) - Apr 2026
Genscript Biotech is a diversified biotechnology group with four key pillars: a foundational and market-leading Life Sciences services and...
149 Views